Novartis AG
TREATMENT OF CANCER USING A CD123 CHIMERIC ANTIGEN RECEPTOR

Abstract:

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.